Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

被引:0
作者
Gross, N [1 ]
Balmas, K
Brognara, CB
Tschopp, J
机构
[1] CHU Vaudois, Univ Hosp, Oncohematol Unit, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 2001年 / 36卷 / 01期
关键词
neuroblastoma; Fas receptor; apoptosis;
D O I
10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Procedure. To determine the possible role of Fas/FasL system in the particularly heterogeneous behaviour of neuroblastoma d(NB), we have measured the functional expression of Fas and its ligand, FasL, in primary neuroblastoma samples and cell lines by immunohistochemistry and flow cytometry. Results. Our results reveal that while Fas expression is associated with low stage and more mature tumors, heterogeneous FasL expression was mostly detected in high stage tumors, with-our apparent correlation to MYCN amplification. Flow cytometric analysis of cell lines demonstrated a high expression of Fas in epithelial-type, HLA class I positive cell lines, which was lost upon activation with phorbol esters. In contrast, Fas ligand was detected in only a small subset of cell lines. Conclusions. In some cell lines, cytotoxic assays revealed the ability of NB-associated Fas receptor to transduce an apoptotic signal upon triggering. The pattern of functional Fas/FasL expression in tumours and cell lines suggests that this system may be involved in the evasion of highly malignant neuroblastoma cells to host immune response. Med. Pediatr. Oncol. 36:111-114, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 13 条
[1]   MOLECULAR-BASIS FOR HETEROGENEITY IN HUMAN NEUROBLASTOMAS [J].
BRODEUR, GM .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :505-510
[2]  
GROSS N, 1990, CANCER RES, V50, P7532
[3]  
GROSS N, 1994, CANCER RES, V54, P4238
[4]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[5]   Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis [J].
Hueber, AO ;
Zornig, M ;
Lyon, D ;
Suda, T ;
Nagata, S ;
Evan, GI .
SCIENCE, 1997, 278 (5341) :1305-1309
[6]  
LAMPSON LA, 1983, J IMMUNOL, V130, P2471
[7]   CYTOLYTIC T-CELL CYTOTOXICITY IS MEDIATED THROUGH PERFORIN AND FAS LYTIC PATHWAYS [J].
LOWIN, B ;
HAHNE, M ;
MATTMANN, C ;
TSCHOPP, J .
NATURE, 1994, 370 (6491) :650-652
[8]   REGULATION OF CELL-SURFACE APO-1/FAS (CD95) LIGAND EXPRESSION BY METALLOPROTEASES [J].
MARIANI, SM ;
MATIBA, B ;
BAUMLER, C ;
KRAMMER, PH .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) :2303-2307
[9]   THE FAS DEATH FACTOR [J].
NAGATA, S ;
GOLSTEIN, P .
SCIENCE, 1995, 267 (5203) :1449-1456
[10]   The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand [J].
OConnell, J ;
OSullivan, GC ;
Collins, JK ;
Shanahan, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1075-1082